Equity Profile

LQDA

Liquidia Corporation

Health CarePharmaceuticals$6.3B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Liquidia Corporation is a pharmaceutical company focused on developing innovative treatments for patients with serious diseases. With a market cap of $6 billion, it operates in the health care sector, which is seeing increased demand for advanced therapies and personalized medicine.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Liquidia is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and fund future innovations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LQDA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+21.08%

Avg Stock Reaction

+4.49%

Last Quarter Recap

In the last quarter, Liquidia reported an EPS of $0.52, significantly beating the estimate of $0.34, which led to a 25.6% increase in stock price the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall financial health.

Management Promises & Guidance

Continued focus on advancing drug development.
Commitment to increasing shareholder value.
Plans to provide more detailed revenue guidance in future reports.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on revenue and future guidance. The strong EPS beat last quarter has raised hopes for continued performance.

Bull Case

If Liquidia can show strong revenue growth and positive updates on its drug pipeline, it could solidify its position as a leader in innovative therapies, leading to further stock appreciation.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or if there are setbacks in drug development, it could lead to a decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate compared to the previous quarter?

Investors will closely watch this metric to gauge the company's ability to sustain momentum after a strong EPS performance.

What updates can management provide on the drug pipeline?

Details on the progress of new treatments will be critical for assessing future revenue potential and market competitiveness.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Liquidia's potential for revenue growth based on its recent EPS performance and pipeline advancements.

Supporting Evidence

The last quarter's EPS beat suggests stronger operational performance than anticipated.

Options pricing indicates a significant expected move, reflecting heightened investor interest.

The company's commitment to advancing its drug pipeline could lead to unexpected revenue streams.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Liquidia can maintain its recent momentum and provide clarity on its future growth prospects.

Bull Confirmed If

Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bullish outlook.

Bear Confirmed If

A revenue decline or lack of pipeline updates would confirm the bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±29.39%

Historical Avg

±6.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±29.4% while LQDA has averaged ±6.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

78.5%

Calls (67K)P/C Ratio: 0.18Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Liquidia beats expectations and raises guidance, history suggests a potential stock increase of around 6.54%, confirming strong operational momentum.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see a muted reaction, reflecting uncertainty.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of 2.44% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue growth figures compared to last quarter.
2Updates on the status of ongoing clinical trials for new drugs.
3Management's outlook on market conditions and competitive landscape.
4Details on cost management strategies and their impact on profitability.
5Any new partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Liquidia is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and fund future innovations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LQDA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+21.08%

Avg Stock Reaction

+4.49%

Last Quarter Recap

Management Promises & Guidance

Continued focus on advancing drug development.
Commitment to increasing shareholder value.
Plans to provide more detailed revenue guidance in future reports.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on revenue and future guidance. The strong EPS beat last quarter has raised hopes for continued performance.

Bull Case

If Liquidia can show strong revenue growth and positive updates on its drug pipeline, it could solidify its position as a leader in innovative therapies, leading to further stock appreciation.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or if there are setbacks in drug development, it could lead to a decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate compared to the previous quarter?

Investors will closely watch this metric to gauge the company's ability to sustain momentum after a strong EPS performance.

What updates can management provide on the drug pipeline?

Details on the progress of new treatments will be critical for assessing future revenue potential and market competitiveness.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Liquidia's potential for revenue growth based on its recent EPS performance and pipeline advancements.

Supporting Evidence

The last quarter's EPS beat suggests stronger operational performance than anticipated.

Options pricing indicates a significant expected move, reflecting heightened investor interest.

The company's commitment to advancing its drug pipeline could lead to unexpected revenue streams.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Liquidia can maintain its recent momentum and provide clarity on its future growth prospects.

Bull Confirmed If

Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bullish outlook.

Bear Confirmed If

A revenue decline or lack of pipeline updates would confirm the bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±29.39%

Historical Avg

±6.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±29.4% while LQDA has averaged ±6.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

78.5%

Calls (67K)P/C Ratio: 0.18Puts (58K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Liquidia beats expectations and raises guidance, history suggests a potential stock increase of around 6.54%, confirming strong operational momentum.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see a muted reaction, reflecting uncertainty.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of 2.44% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific revenue growth figures compared to last quarter.
2Updates on the status of ongoing clinical trials for new drugs.
3Management's outlook on market conditions and competitive landscape.
4Details on cost management strategies and their impact on profitability.
5Any new partnerships or collaborations that could enhance growth prospects.